Loading...
Market
In how many countries will Fibromun be launched by end of 2025?
2
Resolution / Starting Odds
Less than 10 • 25%
10 to 20 • 25%
20 to 30 • 25%
More than 30 • 25%
Sun Pharma's official announcements and press releases
Story
Sun Pharma and Philogen Sign Exclusive Deal to Commercialize Anti-Cancer Drug Fibromun
Oct 1, 2024, 08:52 AM
Sun Pharma has entered into an exclusive global commercialization, licensing, and supply agreement with Swiss-Italian company Philogen to commercialize Fibromun, a specialty cancer anti-cancer immunotherapy drug. This partnership aims to leverage Sun Pharma's extensive market reach to bring Fibromun to a broader range of patients worldwide.
View original story
Similar markets
Less than 5 countries • 25%
5 to 10 countries • 25%
11 to 20 countries • 25%
More than 20 countries • 25%
Less than 5 • 25%
5 to 10 • 25%
11 to 15 • 25%
More than 15 • 25%
1-3 countries • 25%
4-6 countries • 25%
7-9 countries • 25%
10 or more countries • 25%
Less than 10 • 25%
10 to 20 • 25%
21 to 30 • 25%
More than 30 • 25%
Less than 10 • 25%
10 to 20 • 25%
21 to 30 • 25%
More than 30 • 25%
Less than 10 • 25%
10 to 20 • 25%
20 to 30 • 25%
More than 30 • 25%
0-10 • 25%
11-30 • 25%
31-60 • 25%
61-120 • 25%
0-10 • 25%
11-30 • 25%
31-60 • 25%
61+ • 25%
Less than 10 • 25%
10 to 20 • 25%
21 to 30 • 25%
More than 30 • 25%
0-10 countries • 25%
11-20 countries • 25%
21-30 countries • 25%
31 or more countries • 25%
1-4 countries • 25%
5-9 countries • 25%
10-14 countries • 25%
15 or more countries • 25%
1 to 5 countries • 25%
6 to 10 countries • 25%
11 to 15 countries • 25%
More than 15 countries • 25%